(R)-N-[2,3-DIHYDRO-1-[2-(2-METHYLPHENYL)-2-OXOETHYL]-2-OXO-5-PHENYL-1H-1,4-BENZODIAZEPIN-3-YL]-N'-(3-METHYLPHENYL)-UREA
(R)-N-[2,3-DIHYDRO-1-[2-(2-METHYLPHENYL)-2-OXOETHYL]-2-OXO-5-PHENYL-1H-1,4-BENZODIAZEPIN-3-YL]-N'-(3-METHYLPHENYL)-UREA
![(R)-N-[2,3-DIHYDRO-1-[2-(2-METHYLPHENYL)-2-OXOETHYL]-2-OXO-5-PHENYL-1H-1,4-BENZODIAZEPIN-3-YL]-N'-(3-METHYLPHENYL)-UREA 结构式](https://img.chemicalbook.com/CAS/GIF/145084-28-2.gif)
(R)-N-[2,3-DIHYDRO-1-[2-(2-METHYLPHENYL)-2-OXOETHYL]-2-OXO-5-PHENYL-1H-1,4-BENZODIAZEPIN-3-YL]-N'-(3-METHYLPHENYL)-UREA 性质
| 熔点 | 187-190 °C |
|---|---|
| 沸点 | 735.4±60.0 °C(Predicted) |
| 密度 | 1.23±0.1 g/cm3(Predicted) |
| 储存条件 | Store at RT |
| 溶解度 | DMSO：可溶，5mg/mL（澄清溶液） |
| 形态 | 粉末 |
| 酸度系数(pKa) | 11.61±0.40(Predicted) |
| 颜色 | 白色至米色 |
| 旋光性 (optical activity) | [α]/D -128 to -140 (c = 1, DCM) |
(R)-N-[2,3-DIHYDRO-1-[2-(2-METHYLPHENYL)-2-OXOETHYL]-2-OXO-5-PHENYL-1H-1,4-BENZODIAZEPIN-3-YL]-N'-(3-METHYLPHENYL)-UREA 用途与合成方法
|
CCR1 68 pM (Ki) |
CCR2 63 nM (Ki) |
YM022 inhibits binding to canine pancreas CCK-A receptor in a dose-dependent manner, with an IC
50
value for [
3
H]devazepide binding of 136 nM.
YM022 inhibits the binding of [
125
I]CCK-8 to canine cloned gastrin/CCK-B receptor in a dose-dependent manner, with an IC
50
value for [
125
I]CCK-8 binding of 0.73 nM.
Selectivity [ratio of (IC
50
for gastrin/CCK-B receptor)/(IC
50
for CCK-A receptor)] of YM022 is 186.
YM022 (intravenous injection; 0.01-1 μM/kg) dose-dependently inhibits pentagastrin- and peptone meal-induced acid secretion with ED
50
values of 0.0261 and 0.0654 μmol/kg, respectively, without affecting histamine- or methacholine-induced acid secretion.
YM022 (subcutaneous injection; 300 μmol/kg; single dose) lowers the oxyntic mucosal HDC activity and raises the serum gastrin concentration in a dose-dependent manner (measured 24 h after dosage). Maximum enzyme inhibition is achieved at a dose of 300 μmol/kg for YM022 and the inhibition of HDC lasts for 4 weeks. At sacrifice, drug residues can be seen at the injection site for as long as 4 (YM022) weeks after injection in rat.
YM022 is suspended in 2% Methocel for oral ingestion and in PEG300 for subcutaneous injection.
| Animal Model: | Rat |
| Dosage: | 300 μmol/kg |
| Administration: | Subcutaneous injection; 300 μmol/kg; single dose |
| Result: | Suppressed the ECL cell activity for at least 4 as manifested in greatly reduced HDC activity, greatly elevated serum gastrin level. |
(R)-N-[2,3-DIHYDRO-1-[2-(2-METHYLPHENYL)-2-OXOETHYL]-2-OXO-5-PHENYL-1H-1,4-BENZODIAZEPIN-3-YL]-N'-(3-METHYLPHENYL)-UREA 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-04-30 | HY-103355 | 1 mg | 1590 | ||
| 2024-04-30 | HY-103355 | (R)-N-[2,3-DIHYDRO-1-[2-(2-METHYLPHENYL)-2-OXOETHYL]-2-OXO-5-PHENYL-1H-1,4-BENZODIAZEPIN-3-YL]-N'-(3-METHYLPHENYL)-UREA | 145084-28-2 | 5mg | 3500 |
